MetaCap

Clene (CLNN) vs Rafael (RFL)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Rafael (RFL) has outperformed Clene (CLNN) over the past year, losing 25.8% versus a loss of 62.0%. Over five years, RFL leads with a -84.2% price change compared with -96.3% for CLNN. Clene is the larger company by market cap ($50.7 million vs $48.0 million), about 1.1 times the size, while Rafael is growing revenue faster (-4.7% vs -41.5%).

Rafael converts more of its revenue into profit, with a net margin of -3390.7% versus -13086.5%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CLNN-62.03%RFL-25.83%
+218%+69%-80%
Nov 21, 20251 yearNov 20, 2026
CLNN-96.51%RFL-84.64%
+10%-46%-103%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CLNN versus RFL key metrics
MetricCLNNRFL
Share price$3.52$0.9197
Market cap$50.69M$47.99M
1-day change+0.57%+2.19%
YTD return-40.03%-22.06%
1-year return-62.03%-25.83%
5-year return-96.28%-84.19%
EPS (TTM)$-2.30$-0.58
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$200.00K$874.00K
Revenue growth (YoY)-41.52%-4.69%
Net income (latest FY)$-26.17M$-29.64M
Gross margin78.50%—
Operating margin-11541.50%-3822.54%
Net margin-13086.50%-3390.73%
52-week high$10.84$3.96
52-week low$3.02$0.781
Distance from 52-week high-67.53%-76.78%
Analyst consensusnone—
Avg. price target upside+814.77%—
Average volume115.06K140.84K
Shares outstanding14.40M51.39M
Employees7621
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • RFL has outperformed CLNN by 36.2 percentage points over the past year.
  • Rafael is more profitable, keeping -3390.7 cents of every revenue dollar as net income versus -13086.5 cents for Clene.
  • Rafael grew revenue faster in its latest fiscal year (-4.69% vs -41.52%).

About Clene

CLNN stock →

Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. The company's lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases.

Health Care · Biotechnology: Pharmaceutical Preparations · 76 employees

About Rafael

RFL stock →

Rafael Holdings, Inc. primarily engages in holding interests in clinical and early-stage pharmaceutical companies, and medical devices in the United States and Israel.

Health Care · Biotechnology: Pharmaceutical Preparations · 21 employees

CLNN vs RFL FAQ

Which is bigger, Clene or Rafael?

Clene (CLNN) is larger, with a market capitalization of $50.69M compared with $47.99M for Rafael (RFL).

Which stock has performed better over the past year, CLNN or RFL?

RFL returned -25.83% over the past 12 months, compared with -62.03% for CLNN (price return, excluding dividends). Past performance does not predict future results.

Are Clene and Rafael in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons